Literature DB >> 14704820

[Prophylactic pan-coagulation from ischemic central vein occlusions? Practicability of the results from the Central Vein Occlusion Study Group].

I Schmack1, S Dithmar.   

Abstract

PURPOSE: Central vein occlusions (CVO) with an avascular area of more than 10 optic-disc areas are classified as ischemic by the Central Vein Occlusion Study Group (CVOSG). For patients without neovascularizations (NV) clinical controls every 4 weeks during the first 6 months are recommended instead of prophylactic pancoagulation (PC). In this study we examined the practicability of this recommendation. PATIENTS AND METHODS: We analysed the records of 15 patients with ischemic CVO and no clinical signs of NV and no prophylactic PC retrospectively. All these patients developed a neovascular glaucoma (NVG) despite using the criteria of the CVOSG and were then treated with cyclophotocoagulation (CPC).
RESULTS: The time between first presentation and CPC was 4.4+/-2.9 months. Of these patients 7 developed a NVG within 4 weeks after initial presentation.
CONCLUSIONS: This study shows that NV and NVG may develop much faster than 4 weeks and can already be irreversible. Therefore it seems advisable to follow-up patients with increased risk factors even more frequently especially during the initial phase after CVO.

Entities:  

Mesh:

Year:  2003        PMID: 14704820     DOI: 10.1007/s00347-003-0857-4

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  13 in total

1.  Photocoagulation in retinal vein thrombosis.

Authors:  J A Oosterhuis; S C Sedney
Journal:  Ophthalmologica       Date:  1975       Impact factor: 3.250

2.  Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study.

Authors:  S S Hayreh; M R Klugman; P Podhajsky; G E Servais; E S Perkins
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

3.  Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and neovascular glaucoma.

Authors:  L Laatikainen
Journal:  Br J Ophthalmol       Date:  1977-04       Impact factor: 4.638

4.  A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.

Authors: 
Journal:  Ophthalmology       Date:  1995-10       Impact factor: 12.079

5.  Baseline and early natural history report. The Central Vein Occlusion Study.

Authors: 
Journal:  Arch Ophthalmol       Date:  1993-08

6.  [Results of laser coagulation of central retinal vein occlusion].

Authors:  G E Lang
Journal:  Klin Monbl Augenheilkd       Date:  1993-10       Impact factor: 0.700

Review 7.  Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion.

Authors:  S S Hayreh; P Rojas; P Podhajsky; P Montague; R F Woolson
Journal:  Ophthalmology       Date:  1983-05       Impact factor: 12.079

8.  A prospective follow-up study of panretinal photocoagulation in preventing neovascular glaucoma following ischaemic central retinal vein occlusion.

Authors:  L Laatikainen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

9.  The natural course of central retinal vein occlusion.

Authors:  P M Quinlan; M J Elman; A K Bhatt; P Mardesich; C Enger
Journal:  Am J Ophthalmol       Date:  1990-08-15       Impact factor: 5.258

10.  A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation.

Authors:  L L Hansen; P Danisevskis; H R Arntz; G Hövener; M Wiederholt
Journal:  Br J Ophthalmol       Date:  1985-02       Impact factor: 4.638

View more
  3 in total

1.  [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].

Authors:  H P N Scholl; M Fleckenstein; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

2.  [Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland].

Authors:  A E Höh; K B Schaal; S Dithmar
Journal:  Ophthalmologe       Date:  2007-04       Impact factor: 1.059

3.  [Ocular involvement in systemic Loa-Loa filariasis. Case report and review of the literature].

Authors:  A Jaksche; L Wessels; S Martin; K U Loeffler
Journal:  Ophthalmologe       Date:  2004-09       Impact factor: 1.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.